We use cookies to improve site performance and enhance your user experience. If you'd like to disable cookies on this device, please see our cookie management page.
If you close this message or continue to use this site, you consent to our use of cookies on this devise in accordance with our cookie policy, unless you disable them.

Close

registration required

or
for more website access

This content can only be viewed by subscribers and registered users of Investors Chronicle.

Subscribe or register free today

Biotech is back

The biotech sector probably ranks alongside the dot-com boom as one of the worst stock market bubbles to inflate in the past 20 years. From the disaster of British Biotech in the late 1990s to the dispiriting run of business failures since 2007, you could be forgiven for steering well clear. However, something is stirring below the surface as the market starts to reassess the prospects for the survivors and take a renewed interest in what is now a more mature and realistic industry. Furthermore, it is a trend that hasn't escaped the professionals. The International Biotechnology Trust (IBT), as good a barometer as any, recently hit a 10-year share price high of 200p due to surging valuations of quoted companies in the US, which make up the majority of its holdings. The problem is that unless investors are particularly savvy about how the biotech industry works, it is easy to get caught up in short-term trading patterns that cost both time and money, as well as the 'rush for the new' that can characterise the investment approach to biotech.

registration required

visible-status-Subscription-Only story-url-CoverFeature_Biotech_250113.xml

By Julian Hofmann,
25 January 2013

Print this article
Comments

Related Companies

Register today and get...

Register today and get...
Please note terms & conditions apply